Novavax traded at $57.15 this Friday July 1st, increasing $5.72 or 11.12 percent since the previous trading session. Looking back, over the last four weeks, Novavax gained 2.11 percent. Over the last 12 months, its price fell by 73.69 percent. Looking ahead, we forecast Novavax to be priced at 55.60 by the end of this quarter and at 51.20 in one year, according to Trading Economics global macro models projections and analysts expectations.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Peers Price Day Year
Adma Biologics 2.03 0.05 2.53% 30.97%
Agenus 1.96 0.02 1.03% -64.49%
AstraZeneca 10,820.00 12.00 0.11% 24.07%
Astrazeneca 65.95 -0.12 -0.18% 8.49%
BioCryst Pharmaceuticals 10.84 0.26 2.46% -34.22%
Dynavax Technologies 12.96 0.37 2.94% 30.91%
Geron 1.67 0.12 7.74% 14.38%
Genocea Biosciences 0.02 -0.002 -11.76% -99.33%
GlaxoSmithKline 1,797.20 -5.40 -0.30% 25.31%
MannKind 3.98 0.17 4.46% -26.30%
Merck & Co 92.42 1.25 1.37% 17.58%
Moderna Inc 149.95 7.10 4.97% -36.00%
Minerva Neurosciences 3.59 0.28 8.46% 54.74%
Novavax 57.15 5.72 11.12% -73.69%
Novartis 84.36 -0.17 -0.20% -8.28%
Pfizer 52.31 -0.12 -0.23% 31.66%
Peregrine Pharmaceuticals 15.33 0.07 0.46% -41.38%
Cassava Sciences Inc. 26.51 -1.61 -5.73% -70.56%
Sanofi 98.18 -0.16 -0.16% 13.15%
Sarepta Therapeutics 75.71 0.75 1.00% 0.62%
TG Therapeutics 4.57 0.32 7.53% -88.61%

Indexes Price Day Year
USND 11128 99.11 0.90% -23.99%
US2000 1728 19.77 1.16% -25.07%

Novavax
Novavax, Inc. is a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants. The Company operates through developing recombinant vaccines segment. The Company, through its recombinant nanoparticle vaccine technology, produces vaccine candidates to respond to both known and newly emerging diseases. The Company's product pipeline focuses on a range of infectious diseases with vaccine candidates in clinical development for respiratory syncytial virus (RSV), seasonal influenza, pandemic influenza and the Ebola virus (EBOV). The Company's lead adjuvant for human applications, Matrix-M, is in a Phase I/II clinical trial for pandemic influenza H7N9 vaccine candidate. It is also testing Matrix-M in conjunction with its EBOV vaccine candidate in a Phase I clinical trial. It is developing additional pre-clinical stage programs in a range of infectious diseases, including Middle East respiratory syndrome (MERS).